#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic graft versus host disease Trigeminal neuralgia Lymphatic malformation Hepatocellular carcinoma Enteritis Chondrosarcoma Endometrial cancer Thalassaemia Small cell lung cancer extensive stage Glycogen storage disease type II Gastrointestinal stromal tumour Cerebral amyloid angiopathy Complex regional pain syndrome Non-Hodgkin's lymphoma Autoimmune haemolytic anaemia More trials…

    Learn about Rare Diseases

    CADASIL – Diagnostics Waldenstrom’s macroglobulinaemia refractory – Life with Disease Amyotrophic lateral sclerosis – Diagnostics Cystic fibrosis – Treatment Antithrombin III deficiency – Diagnostics Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Medulloblastoma – Life with Disease Factor VIII deficiency – Basic Information Short-bowel syndrome – Treatment Bronchopulmonary dysplasia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tamoxifen Citrate Carbamazepine AUROCELL-TX Azathioprine Prednisone Ht-29-B SURVODUTIDE Dronabinol Abrocitinib Calcium Chloride Dihydrate Bortezomib Midazolam Ng004 Pertechnetate (99Mtc) Sodium Repotrectinib Baloxavir Marboxil Peboctocogene Camaparvovec Gozetotide CHOLINE ALFOSCERATE Tasipimidine More therapies…

    Learn about Your Condition

    Hot flush Pseudomyxoma peritonei Habitual abortion Carcinoid syndrome Carpal tunnel syndrome Asymptomatic HIV infection Aplastic anaemia Muscular dystrophy Lumbosacral radiculopathy Pleural mesothelioma malignant Electrocorticogram Pyelonephritis acute Muscle hypertrophy Ventricular fibrillation Endometrial cancer stage II More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Varsinais-Suomen hyvinvointialue

Varsinais-Suomen hyvinvointialue

Kiinamyllynkatu 4-8, Turku, 20520, Finland

Want to learn more about this study or check if you can participate? Contact us.

  • Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    Denmark Finland France Italy The Netherlands Poland +2

  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7

  • Zongertinib for Cancer in Patients Eligible for Early Access Treatment

    Recruiting

    2 1 1
    Investigated Drugs:
    • Zongertinib
    Finland

  • A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    Austria Belgium Denmark Estonia Finland Germany +8

  • Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Obinutuzumab
    • Pirtobrutinib
    • Venetoclax
    Austria Belgium Czechia Denmark Finland France +8

  • Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Revumenib
    • Azacitidine
    • Venetoclax
    Austria Belgium Denmark Estonia Finland France +8

  • Study on Betamethasone Sodium Phosphate to Prevent Asthma in Children with First-time Rhinovirus-induced Wheezing

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bronchiolitis
    • Wheezing
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    Finland Norway Sweden

  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Ewing’s sarcoma
    • Ewing’s sarcoma metastatic
    • Ewing’s sarcoma recurrent
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Etoposide Phosphate
    • Temozolomide
    Austria Belgium Czechia Denmark Finland France +4

  • Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Vinblastine Sulfate
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia Finland France Germany +4

  • Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    • Methotrexate
    Austria Belgium Czechia Finland France Germany +5
1 2 3 4
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!